Advancing global sepsis trials with AI
Microbio and ARM Hub begin phase two of an AI data platform built to support global clinical trials of the InfectID-BSI sepsis test.
Queensland-based biotech start-up Microbio is working with ARM Hub to make sepsis detection faster and more accurate as they now progress into their second phase together.
In 2023, Microbio asked a critical question: can improved data management support global clinical trials? The answer was a platform that centralises, cleans and streamlines data to improve analytics and functionality.
Speeding Life-Saving Diagnosis
InfectID BSI, Microbio's innovative diagnostic assay, detects 26 sepsis-causing pathogens directly from whole blood in under three hours.
Today, the AI platform supports testing of patient samples directly from blood compared to traditional blood culture results with the new InfectID BSI test.
Transition to Global-Scale Adoption
The project's second phase will support platform integration at clinical trial sites, and focus on feedback on usability and functionality. This stage precedes an upcoming rollout to European clinical sites, where teams will begin using the platform as the first step to record patient result information.
"At the moment, we are making some refinements before going into actual testing where we will move from receiving secondary data to actually collecting primary data," said Charlotte Birkinshaw, AI Engineer at ARM Hub.
The phase will see improvements to portal usability, workflow alignment, and automation of run file processing, ensuring sites can upload data easily and consistently. By making the platform intuitive, the aim is to increase clinical site uptake and reduce friction in early adoption.
"This phase will be driven by human feedback, what they think of the platform, how it works with their actual processes and what can be improved."
Together, ARM Hub and Microbio are building a foundation for faster, cleaner and more reliable global sepsis trial data, enabling stronger clinical evidence and confident commercialisation of InfectID BSI.
"The data foundation we built with ARM Hub enables Microbio to run clinical trials across many markets with a lean team, and keep our focus where it counts, on getting a faster, more accurate result to the clinician," said Flavia Huygens, Executive Director, Founder & CSO at Microbio.
"As we move toward global commercialisation of the InfectID-BSI product, that capability is what will let us grow without losing what makes the science work."